05-09-2014, 05:26 PM
Whether or not mucuna is safer than L-DOPA for Parkinson's patients is irrelevant to performing a risk-benefit calculation for a healthy person. In this study, mucuna caused the same dyskinesias as L-DOPA/carbidopa. Who wants to risk damaging their nervous system just to lower prolactin?
Mucuna is not a promising treatment for addiction or depression. A PubMed search yields zero hits. It's not on any professional's radar, and for good reason. As a rule of thumb, first you choose receptor inhibitors. If that doesn't work you try receptor agonists. Only after failing those two do you dare trying neurotransmitter precursors.
Mucuna is not a promising treatment for addiction or depression. A PubMed search yields zero hits. It's not on any professional's radar, and for good reason. As a rule of thumb, first you choose receptor inhibitors. If that doesn't work you try receptor agonists. Only after failing those two do you dare trying neurotransmitter precursors.